Cargando…

Tolerance of Prolonged Oral Tedizolid for Prosthetic Joint Infections: Results of a Multicentre Prospective Study

Objectives: Data on clinical and biological tolerance of tedizolid (TZD) prolonged therapy are lacking. Methods: We conducted a prospective multicentre study including patients with prosthetic joint infections (PJIs) who were treated for at least 6 weeks but not more than 12 weeks. Results: Thirty-t...

Descripción completa

Detalles Bibliográficos
Autores principales: Senneville, Eric, Dinh, Aurélien, Ferry, Tristan, Beltrand, Eric, Blondiaux, Nicolas, Robineau, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824147/
https://www.ncbi.nlm.nih.gov/pubmed/33374817
http://dx.doi.org/10.3390/antibiotics10010004
_version_ 1783640005814517760
author Senneville, Eric
Dinh, Aurélien
Ferry, Tristan
Beltrand, Eric
Blondiaux, Nicolas
Robineau, Olivier
author_facet Senneville, Eric
Dinh, Aurélien
Ferry, Tristan
Beltrand, Eric
Blondiaux, Nicolas
Robineau, Olivier
author_sort Senneville, Eric
collection PubMed
description Objectives: Data on clinical and biological tolerance of tedizolid (TZD) prolonged therapy are lacking. Methods: We conducted a prospective multicentre study including patients with prosthetic joint infections (PJIs) who were treated for at least 6 weeks but not more than 12 weeks. Results: Thirty-three adult patients of mean age 73.3 ± 10.5 years, with PJI including hip (n = 19), knee (n = 13) and shoulder (n = 1) were included. All patients were operated, with retention of the infected implants and one/two stage-replacements in 11 (33.3%) and 17/5 (51.5%/15.2%), respectively. Staphylococci and enterococci were the most prevalent bacteria identified. The mean duration of TZD therapy was 8.0 ± 3.27 weeks (6–12). TZD was associated with another antibiotic in 18 patients (54.5%), including rifampicin in 16 cases (48.5). Six patients (18.2%) had to stop TZD therapy prematurely because of intolerance which was potentially attributable to TZD (n = 2), early failure of PJI treatment (n = 2) or severe anaemia due to bleeding (n = 2). Regarding compliance with TZD therapy, no cases of two or more omissions of medication intake were recorded during the whole TZD treatment duration. Conclusions: These results suggest good compliance and a favourable safety profile of TZD, providing evidence of the potential benefit of the use of this agent for the antibiotic treatment of PJIs.
format Online
Article
Text
id pubmed-7824147
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78241472021-01-24 Tolerance of Prolonged Oral Tedizolid for Prosthetic Joint Infections: Results of a Multicentre Prospective Study Senneville, Eric Dinh, Aurélien Ferry, Tristan Beltrand, Eric Blondiaux, Nicolas Robineau, Olivier Antibiotics (Basel) Article Objectives: Data on clinical and biological tolerance of tedizolid (TZD) prolonged therapy are lacking. Methods: We conducted a prospective multicentre study including patients with prosthetic joint infections (PJIs) who were treated for at least 6 weeks but not more than 12 weeks. Results: Thirty-three adult patients of mean age 73.3 ± 10.5 years, with PJI including hip (n = 19), knee (n = 13) and shoulder (n = 1) were included. All patients were operated, with retention of the infected implants and one/two stage-replacements in 11 (33.3%) and 17/5 (51.5%/15.2%), respectively. Staphylococci and enterococci were the most prevalent bacteria identified. The mean duration of TZD therapy was 8.0 ± 3.27 weeks (6–12). TZD was associated with another antibiotic in 18 patients (54.5%), including rifampicin in 16 cases (48.5). Six patients (18.2%) had to stop TZD therapy prematurely because of intolerance which was potentially attributable to TZD (n = 2), early failure of PJI treatment (n = 2) or severe anaemia due to bleeding (n = 2). Regarding compliance with TZD therapy, no cases of two or more omissions of medication intake were recorded during the whole TZD treatment duration. Conclusions: These results suggest good compliance and a favourable safety profile of TZD, providing evidence of the potential benefit of the use of this agent for the antibiotic treatment of PJIs. MDPI 2020-12-23 /pmc/articles/PMC7824147/ /pubmed/33374817 http://dx.doi.org/10.3390/antibiotics10010004 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Senneville, Eric
Dinh, Aurélien
Ferry, Tristan
Beltrand, Eric
Blondiaux, Nicolas
Robineau, Olivier
Tolerance of Prolonged Oral Tedizolid for Prosthetic Joint Infections: Results of a Multicentre Prospective Study
title Tolerance of Prolonged Oral Tedizolid for Prosthetic Joint Infections: Results of a Multicentre Prospective Study
title_full Tolerance of Prolonged Oral Tedizolid for Prosthetic Joint Infections: Results of a Multicentre Prospective Study
title_fullStr Tolerance of Prolonged Oral Tedizolid for Prosthetic Joint Infections: Results of a Multicentre Prospective Study
title_full_unstemmed Tolerance of Prolonged Oral Tedizolid for Prosthetic Joint Infections: Results of a Multicentre Prospective Study
title_short Tolerance of Prolonged Oral Tedizolid for Prosthetic Joint Infections: Results of a Multicentre Prospective Study
title_sort tolerance of prolonged oral tedizolid for prosthetic joint infections: results of a multicentre prospective study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824147/
https://www.ncbi.nlm.nih.gov/pubmed/33374817
http://dx.doi.org/10.3390/antibiotics10010004
work_keys_str_mv AT sennevilleeric toleranceofprolongedoraltedizolidforprostheticjointinfectionsresultsofamulticentreprospectivestudy
AT dinhaurelien toleranceofprolongedoraltedizolidforprostheticjointinfectionsresultsofamulticentreprospectivestudy
AT ferrytristan toleranceofprolongedoraltedizolidforprostheticjointinfectionsresultsofamulticentreprospectivestudy
AT beltranderic toleranceofprolongedoraltedizolidforprostheticjointinfectionsresultsofamulticentreprospectivestudy
AT blondiauxnicolas toleranceofprolongedoraltedizolidforprostheticjointinfectionsresultsofamulticentreprospectivestudy
AT robineauolivier toleranceofprolongedoraltedizolidforprostheticjointinfectionsresultsofamulticentreprospectivestudy